U.S. Consumer Advocate Urges U.S. Inspection Of Shanghai Hualian Plants
This article was originally published in PharmAsia News
Executive Summary
A U.S. consumer advocate says the U.S. FDA should inspect immediately all the plants of China's Shanghai Hualian drug maker in the wake of last year's scandal at one of its plants. Two officials of Shanghai Hualian, a division of Shanghai Pharmaceutical Group, were detained by Shanghai police during an investigation after nearly 200 cancer patients were harmed by Hualian leukemia drugs made at one of the division's plants that also produces mifepristone. The drug ingredient is the primary ingredient in the abortion drug RU-486. The division is the sole supplier of the controversial abortion drug, but a Shanghai regulator said the leukemia and RU-486 drugs were made at two different plants. Danco Laboratories has U.S. clearance for the drug as Mifeprex. (Click here for more